Madhav V. Dhodapkar

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Supplementary Table 2: Antibodies used for immune-phenotyping (CyTOF analysis). Supplementary Table 3: Antibodies used for flow cytometry. Supplementary Table 4: Antibodies used for AIM Assay (CyTOF analysis).

Year:

2025

Multiple myeloma (MM) is an incurable malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune factors driving treatment response and resistance, we conducted multi-omics profiling including CD138 neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138 pos bulk RNA and whole-genome sequencing from 209 samples. Longitudinal analyses revealed that interferon gamma signaling impairs T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e -4 ). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell genes in monocytes, and T cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression. Statement of Significance Longitudinal profiling of multiple myeloma and the immune microenvironment revealed dynamic immune-tumor interactions across the disease course. Dysfunctional CD8⁺ T cells limited memory formation post-transplant, while naïve B recovery associated with sustained treatment response. At progression, cancer-testis antigen expression associated with immunosuppression, revealing novel mechanisms of immune escape.

Year:

2025

Lenalidomide, bortezomib and dexamethasone (RVd) has previously been established as standard of care induction therapy for newly diagnosed multiple myeloma (NDMM). More recently, randomized phase 3 data have demonstrated the benefit of the addition of daratumumab (Dara-RVd) to the RVd backbone in terms of improved both depth of response and long-term survival benefit as measured by progression free survival (PFS). Our group has previously published on a historical cohort of 1000 NDMM patients uniformly treated with RVd induction with impressive both PFS and overall survival. Here, we present a comparative analysis of our RVd cohort with a contemporary cohort of 326 patients induced with Dara-RVd at our institution with intent to transplant. This analysis demonstrates the utility of this regimen in real-world clinical practice, and provides additional insights into D-RVd performance in patient subsets often underrepresented in clinical trials, as well as the impact of daratumumab in maintenance for all NDMM patients.

Year:

2024

Newer immune-based approaches based on recruitment and redirection of endogenous and/or synthetic immunity such as chimeric antigen receptor T cells or bispecific antibodies are transforming the clinical management of multiple myeloma (MM). Contributions of the immune system to the antitumor effects of myeloma therapies are also increasingly appreciated. Clinical malignancy in MM originates in the setting of systemic immune alterations that begin early in myelomagenesis and regional changes in immunity affected by spatial contexture. Preexisting and therapy-induced changes in immune cells correlate with outcomes in patients with MM including after immune therapies. Here, we discuss insights from and limitations of available data about immune status and outcomes after immune therapies in patients with MM. Preexisting variation in systemic and/or regional immunity is emerging as a major determinant of the efficacy of current immune therapies as well as vaccines. However, MM is a multifocal malignancy. As with solid tumors, integrating spatial aspects of the tumor and consideration of immune targets with the biology of immune cells may be critical to optimizing the application of immune therapy, including T-cell redirection, in MM. We propose 5 distinct spatial immune types of MM that may provide an initial framework for the optimal application of specific immune therapies in MM: immune depleted, immune permissive, immune excluded, immune suppressed, and immune resistant. Such considerations may also help optimize rational patient selection for emerging immune therapies to improve outcomes.

Year:

2024

Summary Blockade of immune checkpoints has transformed the therapy of several cancers. However, immune‐related adverse events (irAEs) have emerged as a major challenge limiting the clinical application of this approach. B cells are recognized as major players in the pathogenesis of human autoimmunity and have been successfully targeted to treat these disorders. While T cells have been extensively studied as therapeutic targets of immune checkpoint blockade (ICB), these checkpoints also impact B cell tolerance. Blockade of immune checkpoints in the clinic is associated with distinct changes in the B cell compartment that correlate with the development of irAEs. In this review, we focus on the possible role of humoral immunity, specifically human B cell subsets and autoantibodies in the pathogenesis of ICB‐induced irAEs. There remains an unmet need to better understand the T:B cell cross talk underlying the activation of pathogenic B cells and the development of ICB‐induced irAEs. Such studies may identify new targets or approaches to prevent or treat irAEs and improve the application of ICB therapy in cancer.

Year:

2023

Collaborators (25)

Vikas Gupta

Emory University

UNITED STATES
View details

Rafi Ahmed

Emory University School of Medicine

UNITED STATES
View details

Shaji Kumar

Medical College of Wisconsin

UNITED STATES
View details

Jonathan Kaufman

Winship Cancer Institute of Emory University

UNITED STATES
View details

Alberto Moreno

Emory University

UNITED STATES
View details

Renee Julia Manalo

Emory University

UNITED STATES
View details

Manoj Bhasin

Director, Genomics, Proteomics, Bioinformatics and Single cell Biology

Children's Healthcare of Atlanta

UNITED STATES
View details

Ioannis Vlachos

Broad Institute

UNITED STATES
View details

David Avigan

Vice Chair of Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details

Kelly Manning

Staff Scientist

Emory University

UNITED STATES
View details

Mehul S. Suthar

Emory University School of Medicine

UNITED STATES
View details

Sagar Lonial

-

UNITED STATES
View details

Craig Hofmeister

Professor

Emory University

UNITED STATES
View details

Rafi Ahmed

Emory University School of Medicine

UNITED STATES
View details

Mehmet Samur

Senior Research Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Ajay K. Nooka

Professor

Emory University

UNITED STATES
View details

Ravi Vij

Washington University School of Medicine

UNITED STATES
View details

Nisha Joseph

Associate Professor

Winship Cancer Institute of Emory University

UNITED STATES
View details

Alessandro Sette

Professor and Member

La Jolla Institute for Immunology

UNITED STATES
View details

Kavita M. Dhodapkar

Emory University

UNITED STATES
View details

Edgar Ernesto Gonzalez Kozlova

Assistant Professor

-

UNITED STATES
View details

Lawrence Boise

Professor

Emory University

UNITED STATES
View details

Jeffrey Switchenko

Emory University

UNITED STATES
View details

Daniel W. Sherbenou

Associate Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Jonathan Keats

Director of Bioinformatics / Assistant Professor

Translational Genomics Research Institute

UNITED STATES
View details